Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs
Advertisement

Related Content

India Maintains Status Quo On Compulsory Licensing Provisions
India Maintains Status Quo On Compulsory Licensing Provisions; Indian, MNC Lobbies Welcome Moves To Keep Flexibility But Future Doubts Linger
Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
India Story Tempered? Govt. May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments
India Story Tempered? Government May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments
Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
India's Health Minister Hits Out At Buyouts By Foreign Drug Makers; Are Investment Restrictions In The Cards?
PhamAsia News Top Editors' Picks Of 2010
Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations
Stage Set For India To Frame Compulsory Licensing Provisions As Contrasting Groups Make Their Case
Advertisement
UsernamePublicRestriction

Register

SC075739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel